Cellular Bases for Patient Response to Conventional Cancer Therapies Programme

Berlin, Germany

1 - 3 November 2022

Scientific Programme

Tuesday 1st November 2022

Listed times are in Central European Time (CET)

12:00 REGISTRATION & WELCOME LUNCH

13:00 CONFERENCE WELCOME

SESSION 1: TARGETING ORGANELLES FOR THERAPY

Chair: Hugues de Thé

13:10 OPENING KEYNOTE LECTURE

Anthony Letai

Harvard University, USA

"The mitochondrial basis for clinical efficacy of conventional chemotherapy"

Q&A: 13:40-13:55

13:55 **Maria Rescigno**

Humanitas University, Italy

"Microbiota in cancer progression and metastasis"

Q&A: 14:15 - 14:25

14:25 **Martin Higgs**

University of Birmingham, UK

Proffered Paper 1: "A novel epigenetic mechanism for PARPi resistance in BRCA1-deficient tumour cells"

Q&A: 14:35 - 14:40

14:40 EXHIBITOR INTRODUCTIONS

60-second intro pitches by each company

14:50 COFFEE BREAK & TRADE

15:20 **Jean-Emmanuel Sarry (Virtual Presentation)**

CRCT, France

"Mitochondrial adaptation as a Darwinian mechanism of resistance to drugs in leukemia"

Q&A: 15:40 - 15:50

15:50 POSTER SPOTLIGHTS

3 top abstracts presented as 3 minute flash talks

16:00 MEET THE EXPERT TALK

Jos Jonkers & Maria Rescigno

Prof Jonkers and Prof. Dr. Rescigno will host an informal session where they will both share their own personal and professional experiences of their paths to scientific leadership.

Q&A: 16:30 - 16:45

16:45 WELCOME RECEPTION
Drinks reception with buffet served from 17:00

17:45 POSTER DISCUSSION SESSION 1

Wednesday 2nd November 2022

Listed times are in Central European Time (CET)

08:30 POSTER VIEWING
Posters may be freely viewed

SESSION 2: BREAST CANCER: OLD TARGETS, NEW APPROACHES
Chair: Sandra Demaria

09:00 **Jason Carroll**
University of Cambridge, UK
"The role of transcription factors in primary ER+ breast cancer and in metastasis"

Q&A: 09:20 - 09:30

09:30 **Mathias Dahlmann**
Max-Delbrück-Center for Molecular Medicine, Germany
Proffered Paper 2: "PDX models as suitable tools to identify response patterns and novel treatment options in highly heterogeneous tumors"

Q&A: 09:40 - 09:45

09:45 **Cathrin Brisken**
EPFL, Switzerland
"Taming hormone-sensitive breast cancer"

Q&A: 10:05 - 10:15

10:15 **Jos Jonkers**
NKI, Netherlands
"Understanding and overcoming resistance to PARP inhibitors in cancer therapy"

Q&A: 10:35 - 10:45

10:45 COFFEE BREAK & TRADE

11:15 THE EMBO KEYNOTE LECTURE
Fatima Mechta-Grigoriou
Institut Curie, France
"Role of fibroblast heterogeneity in immunosuppression and resistance to immunotherapy"

Q&A: 11:35-11:45

11:45 **Stefan Florian**
Charité University Hospital, Germany
Proffered Paper 3: "Microtubule binding drugs as a phenotype specific targeted cancer therapy"

Q&A: 11:55 - 12:00

12:00 **Lisa Derosa**
Institute Gustave Roussy, France
"Targeting Gut and Tumour Microbiota to Increase Cancer Immunotherapy

Efficacy"

Q&A: 12:20 - 12:30

12:30 POSTER SPOTLIGHTS
3 top abstracts presented as 3 minute flash talks

12:40 LUNCH

13:40 POSTER DISCUSSION SESSION 2

SESSION 3: NEW LIVES FOR CHEMO
Chair: Sophie Postel-Vinay

15:10 **Michael Hemann**
MIT, USA
"What chemotherapy can tell us about tumor cell dependencies"

Q&A: 15:30 - 15:40

15:40 INDUSTRY SPOTLIGHT - STANDARD BIOTOOLS
Melissa Klug
"Ready-to-use 45+ flow cytometry marker panels to measure activation, cytokine production and cytotoxicity from <300ul of whole blood"

15:55 COFFEE BREAK & TRADE

16:40 **Maria Secrier**
UCL Genetics Institute, UK
Proffered Paper 4: "A novel quiescence signature captures rapid drug tolerance development in cancer persister cells"

Q&A: 16:50 - 16:55

16:55 **Vinu Jose (Virtual Presentation)**
Institut Jules Bordet - Universite Libre du Bruxelles, Belgium
Proffered Paper 5: "Microtubule targetting agents affect the clinical benefit of immune response in early breast cancer"

Q&A: 17:05 - 17:10

17:10 **Hugues de Thé**
Institut Jean Bernard, France
"From nuclear architecture to leukemia cure: emerging roles of PML"

Q&A: 17:30 - 17:40

18:30 CONFERENCE DINNER
30-minute drinks reception before the dinner at 19:00. Optional ticketed event.

Thursday 3rd November 2022

Listed times are in Central European Time (CET)

08:45 POSTER VIEWING

09:45 SESSION 4: EXPLOITING CYTOPLASMIC DNA SENSING FOR THERAPY
Chair: Sophie Postel-Vinay

09:45 **Kalle Sipila**
King's College London, UK
Proffered Paper 6: "Mutational heterogeneity and drug response in oral squamous cell carcinoma"

Q&A: 09:55 - 10:00

10:00 **Sophie Postel-Vinay**
Gustave Roussy, France
"Harnessing genetic vulnerabilities in immuno-oncology: novel therapeutic opportunities"

Q&A: 10:20 - 10:30

10:30 COFFEE BREAK & TRADE

11:00 **Priyanka Bhosale**
Kings College London, UK
Proffered Paper 7: "Apoptosis of tumour infiltrating lymphocytes is a mechanism of tumour resistance in OSCC"

Q&A: 11:10 - 11:15

11:15 **Olivia Ciampa**
Garvan Institute of Medical Research, Australia
Proffered Paper 8: "Senescence Reprogramming in ER+ Breast Cancer"

Q&A: 11:25 - 11:30

11:30 CLOSING KEYNOTE LECTURE
Sandra Demaria
Weill Cornell Medicine, USA
"Cancer cell-intrinsic and extrinsic innate immune activation induced by radiation"

Q&A: 12:00 - 12:15

12:15 SUMMARY & CLOSE

12:30 DEPART